Strategy of iron supplementation in hemodialysis patients with Roxallistat for renal anemia

Strategy of iron supplementation in hemodialysis patients with Roxallistat for renal anemia: a single-center exploratory randomized controlled study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300078732

Enrollment

Unknown

Registered

2023-12-18

Start date

2023-12-18

Completion date

Unknown

Last updated

2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

renal anemia

Interventions

A:Maintaining ferritin levels between 100~250ng/ml.

B:Maintaining ferritin levels between 250~500ng/ml.

C:Maintaining ferritin levels 500~ng/ml.

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Receiving regular hemodialysis for more than 6 months; Adequate dialysis (=3 times per week and =10 hours/week); At least 18 years old; Application of Roxadustat; Level of Ferritin 200~500ng/mL; Hb 100~120g/L.

Exclusion criteria

Exclusion criteria: Iron hypersensitivity, or other definitively related adverse reactions; Prior administration of rHuEPO exceeding 300U/Kg/W or Daepotin a surpassing 1.5ug/Kg/W; Abnormal hepatic function; Preexisting diagnosis of any form of myeloproliferative disorder; Within a timeframe of 3 months following gastrointestinal hemorrhage; Diagnosis of thrombotic or embolic disease within the past 3 months; Pregnancy or breastfeeding.

Design outcomes

Primary

Measure	Time frame
ratio of Hb concentration and dose of Roxadustat;	—

Countries

China

Contacts

Public ContactNan Hu

Peking University First Hospital

konan112x@163.com+86 138 1050 8646

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026